Last reviewed · How we verify

Metofane (METHOXYFLURANE)

Abbott · FDA-approved withdrawn Small molecule

Metofane works by binding to the GABA-A receptor and anion channel, enhancing the inhibitory effects of GABA to produce sedation and analgesia.

Metofane (methoxyflurane) is a small molecule drug that targets the GABA-A receptor and anion channel. It is owned by Abbott, but its commercial status, including patent status and generic availability, is unknown. The exact indications, half-life, and bioavailability of Metofane are also unclear. As a result, its clinical use and safety profile are not well established. Further research is needed to determine the potential benefits and risks of this medication.

At a glance

Generic nameMETHOXYFLURANE
SponsorAbbott
Drug classmethoxyflurane
TargetGlycine receptor subunit alpha-1, GABA-A receptor; anion channel
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved

Mechanism of action

Imagine your brain is like a busy city with lots of noise and activity. GABA is like a traffic cop that helps calm things down. Metofane helps the traffic cop work better, so the city becomes quieter and less painful.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: